• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Canine diabetes: Potentially pivotal pilot study under way

July 2, 2019
Maureen McKinney, Associate Editorial Director
dvm360, dvm360 August 2019, Volume 50, Issue 8

A new trial led by a Tufts veterinary professor is evaluating whether a long-acting insulin can control diabetes in dogs more effectively (and give their owners a whole lot more freedom).

Diabetes in small animals is a very treatable condition. What's not so easy is managing the disease on a day-to-day basis. Like people, most pets with diabetes require at least daily injections of insulin to process glucose and avoid complications from hyperglycemia.

It's a big commitment on the owner's part, notes Orla Mahony, MVB, DACVIM, a clinical assistant professor at Cummings School of Veterinary Medicine at Tufts University, in a June 25 Tufts blog post. “Diabetic pets typically require an insulin injection twice daily, and those injections are timed-they are not just given whenever you happen to be at home,” she says. “That has an enormous impact on pet owners, who can no longer work late or sleep in on the weekends. For people who need to travel a lot for work, it can be an especially huge issue.”

A new clinical trial from Tufts University Cummings Veterinary Medical Center may change all that. The trial is evaluating the effectiveness of an ultra-long-acting insulin in controlling glucose levels in dogs using only a single weekly injection.

“If it's successful, owners could give their pets an injection just once a week, removing the need to be home at the same time every day,” Dr. Mahoney says in the blog post. “And although the majority of pets take their shots without a bother, some really fight them, so reducing the number of injections would improve quality of life for these animals and their owners.”

Advertisement

To enroll in the trial-which is part of a multi-institutional study that includes the University of Georgia, Louisiana State and the University of California, Davis, along with Tufts-dogs must have stable diabetes and no other health concerns. After a week of glucose monitoring, eligible dogs will receive up to four weekly injections of the new insulin, with a final study visit a week after the last injection. If it's effective in the pet, owners will have the option of continuing to use the insulin at home for a year after the trial ends.

Dr. Mahony tells dvm360 that one dog, Olaf, has completed the study and is staying on the long-acting insulin for now, while another is just starting the trial and others are being screened. The goal is to enroll 10 dogs in the pilot and to launch a similar trial designed for cats later this summer.

Both insulins were created by a Massachusetts biopharmaceutical company that develops products for human and veterinary medicine. According to Dr. Mahony, commercially available long-lasting insulins in human medicine control blood sugar levels for only two or three days.

To learn more about the diabetes clinical trials at Cummings School of Veterinary Medicine, visit the Tufts clinical trials website or email clinicaltrials@tufts.edu.

download issueDownload Issue: dvm360 August 2019

Related Content:

Breaking NewsEndocrinologydvm360 August 2019
Using in-clinic cortisol testing to detect endocrine diseases in dogs
Using in-clinic cortisol testing to detect endocrine diseases in dogs
The American Animal Hospital Association shares new endocrine guidelines
The American Animal Hospital Association shares new endocrine guidelines
The new Shreiber School of Veterinary Medicine breaks ground
The new Shreiber School of Veterinary Medicine breaks ground

Advertisement

Latest News

Drug for acute onset of canine pancreatitis is launched on the US market

New Automatic 2-in-1 Pet Feeder and Water Dispenser launched

PetHub launches AI tools for pet owners

Prairie dog pups emerge from underground at Maryland Zoo

View More Latest News
Advertisement